



Please Direct All Correspondence to Customer Number **20995**

AMENDMENT / RESPONSE TRANSMITTAL


Applicant	:	Fraser et al.
App. No	:	10/614,643
Filed	:	July 7, 2003.
For	:	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS
Examiner	:	Lankford, Jr., Leon B.
Art Unit	:	1651

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on

September 29, 2006

(Date)


Eric S. Furman, Ph.D., Reg. No.45,664

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- Amendment and Response to Office Action in seven (7) pages.
- Interview Summary in two (2) pages

The fee has been calculated as shown below:

FEE CALCULATION				
FEE TYPE		FEES CODE	CALCULATION	TOTAL
Excess Claims	30 - 96 = 0	1202 (\$50)	0 x 50 =	\$0
Excess Independent	1 - 3 = 0	1201 (\$200)	0 x 200 =	\$0
3 Month Extension	1.17(a)(3)	1253 (\$1,020)		\$1,020
			TOTAL FEE DUE	\$1,020

- An extension of time is hereby requested by payment of the appropriate fee indicated above.
- A check in the amount of \$1,020 is enclosed.
- Return prepaid postcard.


10/03/2006 10:01:11 20232324 12314546
PC PROCESS
10/03/2006 10:01:11

Docket No.: CYTH.002DV3
App. No.: 10/614,644

September 29, 2006
Page 2 of 2

Please Direct All Correspondence to Customer Number 20995

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.


Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

2975737\092906\ivo

CYTH.002DV5



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Fraser et al.
Appl. No. : 10/614,643
Filed : July 7, 2003
For : SYSTEMS AND METHODS FOR
TREATING PATIENTS WITH
PROCESSED LIPOASPIRATE
CELLS
Examiner : Lankford Jr., Leon B
Group Art Unit : 1651

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all
marked attachments are being deposited with
the United States Postal Service as first-class
mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on

September 29, 2006

(Date)


Eric S. Furman, Ph.D., Reg. No. 45,664

INTERVIEW SUMMARY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attached interview summary reflects the substance of the personal interview held
between Examiner Lankford and the undersigned on September 13, 2006.

Appl. No. : 10/614,643
Filed : July 7, 2003

SUMMARY OF INTERVIEW

Applicants wish to thank Examiner Lankford for the courtesy extended during the personal interview held on September 13, 2006 and the helpful comments made therein. During the interview between the undersigned and Examiner Lankford, the indefiniteness rejections 35 U.S.C. § 112, second paragraph, the utility rejections raised under 35 U.S.C. §§ 101, and the enablement rejections raised under 35 U.S.C. § 112, first paragraph, raised in the Office Action mailed March 30, 2006 were discussed. The undersigned and the Examiner also discussed proposed claim amendments. The undersigned and the Examiner agreed that a proposed claim directed to a method of processing a cell population that comprises adipose stem cells for reintroduction into a patient, comprising: removing adipose tissue that comprises adipose stem cells from said patient; introducing a first portion of the removed adipose tissue into a self-contained cell processing unit configured to maintain a closed pathway; separating said cell population that comprises said adipose stem cells from non-adipose tissue present in the tissue that was removed from said patient within said self-contained cell processing unit while maintaining said closed pathway; concentrating said cell population that comprises adipose stem cells with said self-contained cell processing unit while maintaining said closed pathway; mixing said concentrated cell population that comprises adipose stem cells with a second portion of adipose tissue within said self-contained cell processing unit while maintaining said closed pathway; and reintroducing said concentrated cell population that comprises concentrated adipose stem cells from said self-contained cell processing unit into said patient, would likely overcome the rejections of record.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 29, 2006

By: ESF

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

2959389\092506